相關主題
商品描述
This book illustrates the significance of probiotics and prebiotics for the management of various types of cancers. The up-to-date chapters provide recent information about the effect of anticancer treatment approaches on gut microbiota, the correlation between ROS and synbiotics for effective cancer treatment, and the influence of synbiotics on inflammation and immune microenvironment for cancer treatment. It also describes the regulatory issues about synbiotics in the management of cancer. This book is an essential resource for scientists working in the field of cancer, pharmaceutical & clinical sciences, and cancer clinicians. This book is also very useful for undergraduate and postgraduate students of Pharmacy and Biotechnology and medical researchers, mainly working in microbiology, immunology, and cancer biology.
作者簡介
Dr. Neeraj Mishra is working as Professor in Amity Institute of Pharmacy, Gwalior since July 2019. Has done his M Pharm and Ph.D. in Pharmaceutics from Dr. H.S. Gour Central University, Sagar (M.P.), India. He is having around twenty years teaching and research experience. He is having around 100 publications of International and National repute in recent concept of novel drug delivery system, localized drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for treatment of breast, colon cancer and neurodegenerative disorders. Dr. Mishra is having total citation 2750; h- index 25 and i- index 32. The total cumulative Impact Factor of his published papers is around 300 (as per SCOPUS). He is also written 5 Books and 9 book chapter in national and international publisher. He has also published 3 International and 3 National patents. Dr. Mishra has also received "Distinguished Professor Award" 2019, from DST- SPAICS in the workshop heldat Smriti College of Pharmaceutical Education and Research, M.P., India. Recently, Dr. Mishra has received "Distinguished Professor Award" 2021 from IPA, MP State Branch, Indore. He also served as Guest Editor of Thematic issue entitled "Nanoparticulate Carriers for the treatment of Infectious Diseases and Cancer", Current Molecular Pharmacology, Volume 14, 2021, Issue number 3, Bentham Sciences, USA.
Dr. Shvetank Bhattis currently working as an Associate Professor in School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra, India. He has done M.Pharm in Pharmacology from Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka and Ph.D. in Neuropharmacology from Birla Institute of Technology & Science (BITS) Pilani, Pilani Campus, Rajasthan. He has total 16 years of industrial and academic research experience. His are of specialization is CNS disorders, pain, inflammation and immunooncology. He is recipient of Prof. Duggirala Visweswaram & Prof. Sreemantalu Satyanarayana Award (Best Paper in Pharmacology-IJPER) in 2012 and 2014. He has published more than 80 papers in various journals of national and international repute. Dr. Bhatt is having total citation 750; h- index 14 and i- index 24. The total cumulative Impact Factor of his published papers is around 140 (as per SCOPUS). He is life member of Association of Pharmaceutical Teachers of India (APTI) and Indian Pharmacological Society (IPS).
Dr. Keshav Raj Paudel is an IASLC early career researcher at the Centre for Inflammation, Centenary Institute/UTS. He completed his Ph.D. (2017) from Mokpo National University, South Korea, and started his first postdoctoral research at the University of Texas Health Science Centre at Houston Texas, USA-2018 on an NIH-funded project. He is an emerging scientist with a good scientific track record demonstrated through his publications and successful grants. After joining UTS in 2019 for a second postdoctoral position, his research trajectory is continuously upraising in the field of translational research with a major focus on pulmonary diseases. As an early career researcher, he is currently leading various in vitro and in vivo projects under the supervision of Prof. Philip Hansbro with his research expertise, to investigate the potential of nano^ $585K) including IASLC ECR fellowship-2019 (lead CI), TSANZ-grant-in-aid-2021 (lead CI), SPHERE seed grant-2020 (co-CI), Triple I- seed grant (co-CI) and UTS seed grant-2021 (co-CI). Since 2015, he has published more than 100 peer-reviewed scientific articles and book chapters (> 50% as first/senior author in leading journals such as European Respiratory Journal, Cell Death and Diseases, Cell reports, Journal of Controlled Release, Medical Journal of Australia, Drug Discover Today, and Antioxidants, with total citation >1800. He is also a journal reviewer of more than 50 journals and has already reviewed more than 140 research papers. As a journal editor, he has handled more than 40 papers so far from Frontiers in Medicine, Frontiers in Pharmacology, Antioxidants, Journal of Immunology Research, Oxidative Medicine and Cellular Longevity Heliyon.
Prof Philip M Hansbro is Director, Centre for inflammation, Centenary Institute/UTS, NHMRC Level 2 Investigator & Conjoint Prof Research Centre for Healthy Lungs Hunter Medical Research Inst/Uni Newcastle. He built & leads an internationally renowned group that investigates the pathogenesis of respiratory diseases (asthma, COPD, IPF, respiratory infections, lung cancer). He has extensive expertise in developing/using mouse models that recapitulate the major features of human disease & state-of-the-art mouse research facilities (incl PC3 for COVI^400 publications; 40% as senior author in high impact journals: 4,000 citations/year.
Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 12 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua research in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua's research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.
作者簡介(中文翻譯)
Dr. Neeraj Mishra自2019年7月起在Amity Institute of Pharmacy, Gwalior擔任教授。他在印度Madhya Pradesh的Dr. H.S. Gour Central University取得藥劑學的碩士學位和博士學位。他擁有約二十年的教學和研究經驗。他在新型藥物傳遞系統、局部藥物傳遞、靶向和控制性藥物傳遞的概念方面發表了約100篇國際和國內知名的論文，用於治療乳腺癌、結腸癌和神經退行性疾病。Mishra博士的總引用次數為2750次，h指數為25，i指數為32。根據SCOPUS的數據，他發表的論文的總累積影響因子約為300。他還在國內外出版商出版了5本書和9章書籍。他還發表了3項國際專利和3項國內專利。Mishra博士還於2019年獲得了DST-SPAICS頒發的「傑出教授獎」，該獎項在印度Madhya Pradesh的Smriti College of Pharmaceutical Education and Research舉行的研討會上頒發。最近，Mishra博士還獲得了印度藥劑師協會MP分會頒發的「傑出教授獎」2021年。他還擔任了Current Molecular Pharmacology期刊的專題編輯，專題名為「用於治療傳染病和癌症的納米載體」，該期刊的卷號為14，2021年，第3期，由美國Bentham Sciences出版。
Dr. Shvetank Bhatt目前在印度馬哈拉施特拉邦普內的Dr. Vishwanath Karad MIT World Peace University的藥學院擔任副教授。他在印度Manipal College of Pharmaceutical Sciences取得藥理學的碩士學位，並在印度比爾拉理工學院比爾拉尼校區獲得神經藥理學的博士學位。他擁有16年的工業和學術研究經驗。他的專業領域是中樞神經系統疾病、疼痛、發炎和免疫腫瘤學。他於2012年和2014年獲得了Duggirala Visweswaram教授和Sreemantalu Satyanarayana教授頒發的最佳藥理學論文獎（IJPER）。他在國內外知名期刊上發表了80多篇論文。Bhatt博士的總引用次數為750次，h指數為14，i指數為24。根據SCOPUS的數據，他發表的論文的總累積影響因子約為140。他是印度藥學教師協會（APTI）和印度藥理學協會（IPS）的終身會員。
Dr. Keshav Raj Paudel是Centenary Institute/UTS的炎症中心的IASLC早期職業研究員。他於2017年在韓國木浦國立大學獲得博士學位，並於2018年在美國德克薩斯州休斯頓的德克薩斯健康科學中心開展了他的第一個博士後研究項目，該項目由美國國立衛生研究院資助。作為一位新興科學家，他通過發表論文和獲得成功的資助展示了良好的科學成就。自2019年加入UTS以來，他在轉化研究領域不斷取得突破，主要研究肺部疾病。作為一位早期職業研究員，他目前在Philip Hansbro教授的指導下領導各種體外和體內項目，研究納米載體在肺部疾病治療中的潛力。他獲得的資助包括IASLC ECR fellowship-2019（主要CI），TSANZ-grant-in-aid-2021（主要CI），SPHERE seed grant-2020（共同CI），Triple I- seed grant（共同CI）和UTS seed grant-2021（共同CI），總金額超過58.5萬美元。自2015年以來，他已在各種國內外知名期刊上發表了100多篇同行評審的科學文章和書籍章節（超過50％作為第一/通訊作者），包括European Respiratory Journal、Cell Death and Diseases、Cell reports、Journal of Controlled Release、Medical Journal of Australia、Drug Discover Today和Antioxidants等，總引用次數超過1800次。他還是50多個期刊的審稿人。
